8-K: Lantheus Merger Antitrust Review Extended

Lantheus Holdings announced a routine withdrawal and resubmission of its HSR filing, extending the antitrust review period for its pending merger with Curium US Holdings LLC.

Summary

• Lantheus Holdings, Inc. has provided an update on its previously announced merger with Curium US Holdings LLC.
• As part of ongoing cooperation with the Federal Trade Commission (FTC) review, the acquiring party voluntarily withdrew its pre-merger Notification and Report Form under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act.
• The form was resubmitted on September 21, 2026, initiating a new 30-day waiting period under the HSR Act, which is now set to expire on October 21, 2026.
• This withdrawal and refiling is described as a routine procedure to allow additional time for antitrust review.
• The company and the acquiring party continue to work constructively with the FTC.
• The expected closing of the merger remains in the first half of 2027, subject to regulatory approvals, stockholder adoption, and other customary conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily due to the routine nature of the HSR filing withdrawal and resubmission, which is common in large mergers. The continued expectation of closing in H1 2027, despite a minor delay in the antitrust review timeline, suggests underlying confidence.

Positives

• The withdrawal and resubmission of the HSR filing is a routine procedural step, indicating ongoing cooperation with regulators.
• The expected closing date for the merger remains in the first half of 2027, suggesting continued confidence in the deal's progression.
• The company and the acquiring party are working constructively with the FTC staff.

Negatives

• The antitrust review period has been extended due to the withdrawal and refiling of the HSR notification.
• The new 30-day waiting period under the HSR Act will expire on October 21, 2026, and could be extended if the FTC requests additional information.

Risks

• Uncertainties as to the timing of the proposed acquisition.
• The possibility that various conditions to the consummation of the proposed acquisition may not be satisfied or waived on the expected timetable, or at all.
• The effects of disruption from the transactions and the impact of the announcement and pendency of the proposed acquisition on Lantheus' business.
• The diversion of management time and attention from ongoing business operations and opportunities.
• Stockholder litigation in connection with the proposed acquisition may result in significant costs of defense, indemnification and liability.
• Parent's ability to obtain financing to complete the proposed acquisition.
• The potential effects of the proposed acquisition on Lantheus' share price.

Future Outlook

The company continues to expect to consummate the Merger in the first half of 2027, subject to the receipt of required regulatory approvals, the adoption of the Merger Agreement by the Company's stockholders, and the satisfaction or waiver of other customary closing conditions. The company also mentions its plans to execute on the commercialization of marketed products, ensure launch readiness for new products, advance a focused late-stage pipeline, and allocate capital thoughtfully, with a focus on its radiodiagnostic business and pursuing value-maximizing alternatives for its radiotherapeutic assets.

Management Comments

• Withdrawing and refiling pre-merger notifications is a routine procedure in order to provide additional time for antitrust review of certain transactions.
• The Company and Parent continue to work constructively with the FTC staff in the FTCs review of the Merger and continue to expect to consummate the Merger in the first half of 2027.

Industry Context

StockSavvy.ai notes that the voluntary withdrawal and refiling of HSR notifications is a common practice in large-scale mergers and acquisitions, particularly in industries subject to significant regulatory scrutiny like healthcare and pharmaceuticals. This action, while extending the review timeline, does not inherently signal a problem with the deal but rather a procedural step to accommodate regulatory diligence.

Legal Proceedings

• Stockholder litigation in connection with the proposed acquisition may result in significant costs of defense, indemnification and liability.

Stakeholder Impact

• Shareholders: The merger's progression and potential closing are significant, with ongoing review potentially impacting share price. Stockholder adoption of the Merger Agreement is a condition to closing.
• Employees: Potential disruption from the transaction and uncertainty regarding integration post-merger.
• Business Partners/Suppliers: The announcement and pendency of the acquisition may affect relationships and operational continuity.
• Competitors: The merger could alter the competitive landscape in the radiodiagnostic and radiotherapeutic markets.

Next Steps

• Continue working constructively with the FTC staff.
• Await expiration or termination of the new 30-day HSR Act waiting period (October 21, 2026).
• Obtain required regulatory approvals.
• Obtain adoption of the Merger Agreement by the Company's stockholders.
• Satisfy or waive other customary closing conditions.
• Consummate the Merger, expected in the first half of 2027.

Key Dates

Recommendation

The filing primarily concerns a procedural update on the antitrust review for a pending merger. While the extension of the review period is a minor delay, the overall deal progression and expected closing timeline remain consistent. There is no new material financial information or significant change in strategic direction that would warrant a buy or sell recommendation at this juncture. Investors should continue to monitor regulatory approvals and the overall progress of the merger.

Keywords

Merger Agreement, Hart-Scott-Rodino Act, Antitrust Review, Federal Trade Commission, Regulatory Approval, Proxy Statement, Stockholder Adoption, Acquisition